Harvard Medical School
Division of Harvard University
Latest From Harvard Medical School
The company closed a $65m Series A round to interrogate single cells involved in diseases and identify genes responsible for their malfunction, providing new targets for precision medicines to treat autoimmune diseases and cancer.
April had four VC rounds of $100m or more, including Allogene's $300m to develop CAR-T therapies licensed from Pfizer. Innovent Biologics raised $150m, BenevolentAI brought in $115m and Constellation garnered $100m last month.
Private Company Edition: Martin Mackay and two other former Alexion executives co-founded the rare disease start-up in January with a $37m Series A to kick things off. Also, Innovent raises $150m in venture cash, Tmunity adds $35m and Third Rock launches Cedilla.
Vanderbilt launches new biotech with Deerfield aimed at reworking the drug development paradigm, while also expanding its cancer research work with BI. Grunenthal partners with Katholieke Universiteit Leuven to investigate ion channel modulation approaches in pain.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.